ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011
Neither IL-17A mRNA nor IL-17A protein are detectable in Langerhans cell histiocytosis lesions.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Merkel cell polyomavirus and Langerhans cell neoplasm.Cell communication and signaling : CCS · 2018Pooled it
- [Immune microenvironment of Langerhans cell histiocytosis: from immune suppression to targeted therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Langerhans cell histiocytosis: current advances in molecular pathogenesis.Frontiers in immunology · 2023Review
- Multisystem Langerhans Cell Histiocytosis in Younger Infants First Presenting in Skin: A Case Series.Journal of personalized medicine · 2022Article
- Langerin-expressing dendritic cells in pulmonary immune-related diseases.Frontiers in medicine · 2022Review
- Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.Frontiers in oncology · 2021Article
- Comparison of three different ELISAs for the detection of recombinant, native and plasma IL-17A.MethodsX · 2020Article
- Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis.Scientific reports · 2018Article
- Langerhans-Cell Histiocytosis.The New England journal of medicine · 2018Review
- Observational
- Effects of β-d-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, onDrug design, development and therapy · 2017Article
- Cell(s) of Origin of Langerhans Cell Histiocytosis.Hematology/oncology clinics of North America · 2015Review
- Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?British journal of haematology · 2015Review
- Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.Cell communication and signaling : CCS · 2015Review
- Article
- New insights into the molecular pathogenesis of langerhans cell histiocytosis.The oncologist · 2014Article
- Article
- IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy.Virchows Archiv : an international journal of pathology · 2013Article
- Pathological consequence of misguided dendritic cell differentiation in histiocytic diseases.Advances in immunology · 2013Review
- Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease characterized by heterogeneous lesions including CD207(+)/CD1a(+) dendritic cells that can result in significant morbidity and mortality. The etiology of LCH remains speculative, and neoplastic and inflammatory origins have been debated for decades. A recent study identified abundant interleukin-17 (IL-17A) protein in dendritic cells in LCH lesions as well as in plasma from patients with active disease. Furthermore, it identified dendritic cells as a novel source of IL-17A expression. However, subsequent studies from our research group failed to identify any IL-17A gene expression from CD207(+) dendritic cells or CD3(+) T cells in LCH lesions. In this study, further investigation once again fails to identify any cells in LCH lesions with IL-17A gene expression. Furthermore, IL-17A antigen is undetectable in LCH lesion lysates with western blotting, immunoprecipitation, spectral analysis, and enzyme-linked immunosorbent assay (ELISA). Western blots, immunoprecipitation, and ELISA experiments also demonstrate that antibodies used in original studies that established the IL-17A hypothesis for pathogenesis of LCH recognize nonspecific proteins. We conclude that evidence for IL-17A as a significant factor in LCH remains inadequate and clinical trials targeting IL-17A remain unjustified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.